On May 26, Ali Health fell 3.12% in regular trading, trading at HK$3.77/share with trading volume of HK$176 million, extending post-earnings weakness.

The decline reflects continued selling pressure after the company reported FY2026 second-half revenue of RMB 17.6 billion, up 7.6% year-over-year, significantly below the market expectation of 13.8% growth. Multiple major banks subsequently cut their target prices: UBS maintained its \"sell\" rating and lowered its target to HK$3.6, cutting earnings forecasts by 12%-14%; Goldman Sachs reduced its target to HK$4.2; CLSA slashed its adjusted net profit forecast by 23%. Analysts broadly cited concerns over margin pressure from increased investment in AI and supply chain infrastructure, as well as a rising mix of lower-margin first-party pharmaceutical sales.

Within the Internet and Direct Marketing Retail sector, the broader healthcare segment traded under pressure, with JD Health down 4.04% and PA Good Doctor down 2.50%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)